The finding, presented at the HIV Drug Therapy Congress in Glasgow, United Kingdom, supports the use of a lower dose of the drug in combination with tenofovir plus emtricitabine as first-line therapy for HIV.
For the full article, click here.
Viral Load Reductions Persist With Less Efavirenz for HIV
[From Medscape, Pam Harrison, Nov 6, 2014] The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.